V Hasselblad
Overview
Explore the profile of V Hasselblad including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
2312
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
OConnor C, Starling R, Hernandez A, Armstrong P, Dickstein K, Hasselblad V, et al.
N Engl J Med
. 2011 Jul;
365(1):32-43.
PMID: 21732835
Background: Nesiritide is approved in the United States for early relief of dyspnea in patients with acute heart failure. Previous meta-analyses have raised questions regarding renal toxicity and the mortality...
2.
Li J, Baker-Smith C, Smith P, Hasselblad V, Murphy M, Califf R, et al.
Clin Pharmacol Ther
. 2008 Jun;
84(3):315-9.
PMID: 18548000
Angiotensin-converting enzyme (ACE) inhibitors are frequently used to treat hypertension in children.(1) ACE inhibitors alter the balance between the vasoconstrictive, salt-retentive, and cardiac hypertrophic properties of angiotensin II and the...
3.
Inrig J, Oddone E, Hasselblad V, Gillespie B, Patel U, Reddan D, et al.
Kidney Int
. 2007 Jan;
71(5):454-61.
PMID: 17213873
The relationship between blood pressure (BP) and clinical outcomes among hemodialysis patients is complex and incompletely understood. This study sought to assess the relationship between blood pressure changes with hemodialysis...
4.
Alexander J, Dyke C, Yang H, Becker R, Hasselblad V, Zillman L, et al.
J Thromb Haemost
. 2004 Mar;
2(2):234-41.
PMID: 14995984
Background: Direct factor (F)Xa inhibition is an attractive method to limit thrombotic complications during percutaneous coronary intervention (PCI). Objectives: To investigate drug levels achieved, effect on coagulation markers, and preliminary...
5.
Newby L, Hasselblad V, Armstrong P, Van de Werf F, Mark D, White H, et al.
Eur Heart J
. 2003 Feb;
24(2):182-9.
PMID: 12573275
Aims: We evaluated timing of adverse cardiac events after thrombolysis to guide length of stay after ST-segment elevation myocardial infarction. Methods And Results: Kaplan-Meier survival curves described timing of major...
6.
McCrory D, Matchar D, Bastian L, Datta S, Hasselblad V, Hickey J, et al.
Evid Rep Technol Assess (Summ)
. 2002 Apr;
(5):1-6.
PMID: 11925972
No abstract available.
7.
Batchelor W, Mahaffey K, Berger P, Deutsch E, Meier S, Hasselblad V, et al.
J Am Coll Cardiol
. 2001 Nov;
38(6):1608-13.
PMID: 11704394
Objectives: We performed a multicenter, double-blind placebo-controlled trial to examine the efficacy and safety of enoxaparin in patients at high risk for stent thrombosis (ST). Background: The optimal antithrombotic regimen...
8.
Shah M, Hasselblad V, Gheorghiade M, Adams Jr K, Swedberg K, Califf R, et al.
Am J Cardiol
. 2001 Nov;
88(9):987-93.
PMID: 11703994
Clinicians have relied on history and results from physical examinations to guide treatment of patients with advanced congestive heart failure, but these results may not reflect disease severity or hemodynamic...
9.
McLaren C, Li K, Gordeuk V, Hasselblad V, McLaren G
Blood
. 2001 Oct;
98(8):2345-51.
PMID: 11588029
In previous analyses of transferrin saturation data in African Americans and Caucasians from the second National Health and Nutrition Examination Survey (NHANES II), subpopulations were found consistent with population genetics...
10.
Seidenfeld J, Piper M, Flamm C, Hasselblad V, Armitage J, Bennett C, et al.
J Natl Cancer Inst
. 2001 Aug;
93(16):1204-14.
PMID: 11504766
Epoetin treatment offers an attractive but costly alternative to red blood cell transfusion for managing anemia associated with cancer therapy. The goal of this review is to facilitate more efficient...